Showing 841 - 860 results of 3,158 for search 'Patient Number 9', query time: 0.09s Refine Results
  1. 841
  2. 842
  3. 843
  4. 844

    Comparison of Nasal Colonization of Methicillin-Resistant Staphylococcus aureus in HIV-Infected and Non-HIV Patients Attending the National Public Health Laboratory of Central Nepa... by Kalash Neupane, Binod Rayamajhee, Jyoti Acharya, Nisha Rijal, Dipendra Shrestha, Binod G C, Mahesh Raj Pant, Pradeep Kumar Shah

    Published 2018-01-01
    “…Among the HIV-infected, patients of age group 31–40 years were the ones with highest carriage rate 36 (45%), while in non-HIV patients, the highest rate 13 (28.9%) of carriage was detected among the patients of age group 21–30 years. …”
    Get full text
    Article
  5. 845
  6. 846

    Delayed PCI 12 Hours after the Onset of Symptoms Is Associated with Improved Outcomes for Patients with ST-Segment Elevation Myocardial Infarction: A Real-World Study by Wen-Juan Xiu, Hai-Tao Yang, Ying-Ying Zheng, Yi-Tong Ma, Xiang Xie

    Published 2019-01-01
    “…The number of all-cause deaths in the delayed PCI group and that in the MT group were 55 (9.3%) and 138 (28.9%), respectively, and a significant difference between the groups was indicated for this variable (P<0.001). …”
    Get full text
    Article
  7. 847

    Impact of pharmacist-led intervention for reducing drug-related problems and improving quality of life among chronic kidney disease patients: A randomized controlled trial. by Roheena Zafar, Inayat Ur Rehman, Yasar Shah, Long Chiau Ming, Khang Wen Goh, Amal K Suleiman, Tahir Mehmood Khan

    Published 2025-01-01
    “…This study was aimed to evaluate the impact of clinical pharmacist-led interventions on the mean number of DRPs and the mean QoL score difference per patient DRPs in CKD patients.…”
    Get full text
    Article
  8. 848
  9. 849
  10. 850
  11. 851

    Correlation between Glycated Hemoglobin Levels and Knowledge, Attitude, and Practice of Type 2 Diabetic Patients Attending Primary Health Care Centers in Dubai Health Authority by Hind Al Razooqi, Bashayer AlNajjar, Ebrahim AlShamsi, Kaltham Ibrahim, Wadeia Sharief, Hamda Khansaheb, Marwan Zidan

    Published 2023-05-01
    “…Knowledge, attitude, and practice (KAP) significantly impact the outcome of self-management in patients with diabetes, yet the association between KAP of type 2 diabetes and the combined control of the glycated hemoglobin (HbA1c) level to date remains uncertain due to lack in the number of studies. …”
    Get full text
    Article
  12. 852
  13. 853
  14. 854
  15. 855

    Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review... by Konstantinos Lallas, Eftychia Chatziioannou, Derya Durak, Georg Frey, Lina Maria Serna-Higuita, Marie-Lena Rasch, Athanassios Kyrgidis, Eleni Timotheadou, Zoe Apalla, Ulrike Leiter, Lukas Flatz, Lukas Flatz, Aimilios Lallas, Teresa Amaral, Teresa Amaral

    Published 2025-01-01
    “…Random-effects models were preferred, and subgroup and sensitivity analyses were conducted to investigate possible sources of heterogeneity.Results38 and 35 studies were included in qualitative and quantitative synthesis, respectively. From 2542 patients discontinued treatment with ICIs electively or due to TLTs, 495 experienced progression [number of studies (n)=34, RR 20.9%, 95%CI 17.1 – 24.7%, I2 85%) and higher rates were detected in patients with TLTs compared to elective discontinuation. …”
    Get full text
    Article
  16. 856

    TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial by Wei Gao, Ping Hu, Aung Naing, Meredith McKean, Anthony Tolcher, Lillian L Siu, Keyvan Tadjalli-Mehr, Anja Victor, Emilia Richter, Marco A F Nogueira Filho, Thomas Kitzing, Stephan Gleicher, Daniel Holland

    Published 2025-02-01
    “…Further evaluation of M6223 is ongoing in combination with the PD-L1 inhibitor avelumab in patients with advanced urothelial carcinoma (JAVELIN Bladder Medley; NCT05327530).Trial registration number NCT04457778.…”
    Get full text
    Article
  17. 857
  18. 858
  19. 859
  20. 860